Campbell & CO Investment Adviser LLC
Position in ENTA — Enanta Pharmaceuticals Inc
CIK 1353570
BALTIMORE, MD
Position in ENTA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$507,902
-$346,027 QoQ
Shares Held
40,214
-25.7% QoQ
Ownership
0.138%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ENTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Campbell & CO Investment Adviser LLC holds $45,287,811 across 43 Biotechnology names. ENTA ranks #24 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
9,034 | $6,597,078 | |
| 2 | KRYS |
Krystal Biotech, Inc.
|
17,795 | $4,596,804 | |
| 3 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
83,617 | $3,036,969 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
29,130 | $2,832,892 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,580 | $2,491,693 | |
| 6 | TECH |
BIO-TECHNE Corp
|
41,339 | $2,160,376 | |
| 7 | RPRX |
Royalty Pharma plc
|
31,202 | $1,496,759 | |
| 8 | PRTA |
Prothena Corp Public Ltd Co
|
142,587 | $1,385,945 |
All Filings in ENTA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $507,902 | 40,214 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $853,929 | 54,149 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $225,694 | 18,855 | Shares | Sole | 2025-10-28 | |
| 2022-09-30 | $674,621 | 13,006 | Shares | Sole | 2022-11-14 | |
| 2021-12-31 | $269,208 | 3,600 | Shares | Sole | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||